Related Experiment Video
Updated: Jul 2, 2026
Orthotopic Ovarian Transplantation Procedures to Investigate the Life- and Health-span Influence of Ovarian Senescence in Female Mice
Published on: February 12, 2018
Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives
Alaa M Alsirhani1, Mohammad El-Nablaway2, Tarek A Yousef3
1Department of Chemistry, College of Science, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia.
Abstract:
Ovarian aging manifests as progressive depletion of the primordial follicle reserve and declining oocyte quality, culminating in menopause and associated systemic comorbidities. Cellular senescence emerges as a central driver of this process, exerting effects through cell-cycle arrest pathways and a proinflammatory senescence-associated secretory phenotype (SASP) that disrupts the follicular niche and stromal architecture. However, current senolytic and senomorphic interventions for ovarian aging remain largely at the mechanistic and preclinical stages, and their translational potential in humans is still uncertain. This review synthesizes the molecular hallmarks of ovarian senescence-encompassing genomic instability, mitochondrial dysfunction, dysregulated nutrient sensing (PI3K/AKT/mTOR), proteostatic failure, epigenetic drift, and inflammasome activation-into a unified framework for therapeutic intervention. We critically evaluate the preclinical efficacy of senolytics (eg, dasatinib + quercetin, navitoclax, fisetin), and senomorphics (eg, rapamycin, metformin, melatonin, NLRP3 inhibitors) in preserving ovarian reserve, mitigating SASP-driven inflammation and fibrosis, and extending reproductive lifespan. Emphasis is placed on multimodal biomarkers (AMH, AFC, SASP analytes, follicular fluid signatures, exosomal RNAs) essential for clinical translation, alongside ovary-directed delivery systems to enhance specificity and safety. By bridging ovarian geroscience with emerging senotherapeutics, this review charts a roadmap for advancing these strategies from bench to bedside, offering potential to combat ovarian aging and safeguard women's reproductive and systemic health.
Insights
Cellular senescence drives ovarian aging and menopause. Senolytic and senomorphic drugs show promise in preclinical studies for preserving ovarian reserve and reproductive lifespan.
Area of Science:
- Geroscience
- Reproductive Biology
- Cellular Biology
Background:
- Ovarian aging involves follicle depletion and oocyte quality decline, leading to menopause and comorbidities.
- Cellular senescence, characterized by cell-cycle arrest and a pro-inflammatory senescence-associated secretory phenotype (SASP), is a key driver of ovarian aging.
- Current senotherapeutic interventions for ovarian aging are primarily in preclinical stages with uncertain human applicability.
Purpose of the Study:
- To synthesize the molecular hallmarks of ovarian senescence into a framework for therapeutic intervention.
- To critically evaluate the preclinical efficacy of senolytics and senomorphics in combating ovarian aging.
- To outline a roadmap for clinical translation of senotherapeutics for ovarian aging.
Main Methods:
- Review and synthesis of molecular hallmarks of ovarian senescence, including genomic instability, mitochondrial dysfunction, and inflammasome activation.
- Critical evaluation of preclinical data on senolytics (e.g., dasatinib + quercetin) and senomorphics (e.g., rapamycin, metformin).
- Assessment of multimodal biomarkers (e.g., AMH, AFC, SASP analytes) and ovary-directed delivery systems for clinical translation.
Main Results:
- Senolytics and senomorphics demonstrate preclinical potential in preserving ovarian reserve and mitigating SASP-driven inflammation and fibrosis.
- Specific senotherapeutics like dasatinib + quercetin, fisetin, rapamycin, and metformin show promise in preclinical models.
- Multimodal biomarkers and targeted delivery systems are crucial for advancing senotherapeutics to clinical application.
Conclusions:
- Cellular senescence is a central mechanism in ovarian aging, offering therapeutic targets.
- Senolytics and senomorphics represent a promising strategy to combat ovarian aging, preserve reproductive lifespan, and improve women's health.
- Bridging geroscience and senotherapeutics, with a focus on biomarkers and delivery, is key for clinical translation.
Related Concept Videos
02:07Oogenesis
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...